Overview AZD4635 Relative Bioavailability Study Status: Completed Trial end date: 2019-04-02 Target enrollment: Participant gender: Summary To investigate the pharmacokinetics and relative bioavailability of AZD4635 solid oral formulation and compare with the nano-suspension reference formulation with the option to assess food effect, pH effect and absolute bioavailability Phase: Phase 1 Details Lead Sponsor: AstraZenecaCollaborator: Quotient SciencesTreatments: DexlansoprazoleLansoprazole